Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer

By LabMedica International staff writers
Posted on 31 Oct 2025

After surgery for muscle-invasive bladder cancer, many patients face uncertainty about whether residual cancer cells remain in their bodies. More...

Now, a new international phase 3 study has demonstrated that a simple blood test detecting circulating tumor DNA (ctDNA) can accurately identify which patients are most likely to benefit from immunotherapy. The findings, published in The New England Journal of Medicine, suggest a precision medicine approach—where treatment is guided by ctDNA results—can improve survival outcomes while sparing others from unnecessary therapy.

In the global, randomized IMvigor011 trial co-led by Dana-Farber Cancer Institute (Boston, MA, USA), Technical University of Munich (Munich, Germany), and Queen Mary University of London (London, UK), more than 800 patients who showed no clinical signs of cancer after surgery were screened for ctDNA every six weeks for up to one year. A total of 250 patients who tested ctDNA-positive—indicating minimal residual disease—were randomized in a 2:1 ratio to receive either atezolizumab, an immune checkpoint inhibitor targeting PD-L1, or a placebo. Patients who remained ctDNA-negative received no additional treatment.

The results were striking: patients who tested ctDNA-positive and received atezolizumab had a 36% lower risk of cancer recurrence compared to those receiving a placebo, and a 41% reduction in risk of death. This benefit was seen both in patients who were ctDNA-positive immediately after surgery and those who became positive later during follow-up.

In contrast, ctDNA-negative patients remained largely cancer-free, with 89% disease-free survival and over 90% overall survival at a median follow-up of 21.8 months—indicating they could safely forgo further therapy. The study builds on earlier research, including the IMvigor010 trial, which showed no overall benefit for atezolizumab when given to all post-surgery patients. However, retrospective data hinted that patients with ctDNA positivity—signifying lingering cancer cells undetectable by conventional scans—did derive benefit.

IMvigor011 was designed to prospectively confirm this hypothesis and is the first trial to show that adjuvant immunotherapy guided by ctDNA testing can improve both disease-free and overall survival. Importantly, no new side effects were reported, reinforcing the safety of atezolizumab in this setting. The trial’s results are expected to influence clinical practice and regulatory guidance by linking immunotherapy use to ctDNA testing.

“This is the first time that an adjuvant immunotherapy trial has shown a survival benefit in patients selected based on ctDNA testing,” said Dr. Joaquim Bellmunt, co-principal investigator of the study. “Patients who are ctDNA-positive benefit significantly from atezolizumab, while those who remain ctDNA-negative can be spared unnecessary treatment.”

Related Links:
Dana-Farber Cancer Institute
Technical University of Munich
Queen Mary University of London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.